Business Description
Arbutus Biopharma Corp
NAICS : 325412
SIC : 3741
ISIN : CA03879J1003
Description
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 88.38 | |||||
| Equity-to-Asset | 0.76 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -3.2 | |||||
| Beneish M-Score | -2.49 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 6.2 | |||||
| 3-Year EBITDA Growth Rate | 17.5 | |||||
| 3-Year EPS without NRI Growth Rate | 23.7 | |||||
| 3-Year FCF Growth Rate | 8.4 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 25.14 | |||||
| 9-Day RSI | 28.1 | |||||
| 14-Day RSI | 31.68 | |||||
| 6-1 Month Momentum % | 14.21 | |||||
| 12-1 Month Momentum % | 46.25 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.02 | |||||
| Quick Ratio | 7.02 | |||||
| Cash Ratio | 6.75 | |||||
| Days Sales Outstanding | 199.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -23.2 | |||||
| Shareholder Yield % | -7.82 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1165.03 | |||||
| Net Margin % | -1137.65 | |||||
| FCF Margin % | -1066.79 | |||||
| ROE % | -67.36 | |||||
| ROA % | -50.87 | |||||
| ROIC % | -317.93 | |||||
| ROC (Joel Greenblatt) % | -1349.5 | |||||
| ROCE % | -59.14 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 84.47 | |||||
| PB Ratio | 5.69 | |||||
| Price-to-Tangible-Book | 5.69 | |||||
| EV-to-EBIT | -6.3 | |||||
| EV-to-EBITDA | -6.35 | |||||
| EV-to-Revenue | 71.48 | |||||
| EV-to-Forward-Revenue | 82.68 | |||||
| EV-to-FCF | -6.7 | |||||
| Price-to-Median-PS-Value | 3.49 | |||||
| Price-to-Net-Current-Asset-Value | 6.17 | |||||
| Price-to-Net-Cash | 6.42 | |||||
| Earnings Yield (Greenblatt) % | -15.87 | |||||
| FCF Yield % | -11.82 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Arbutus Biopharma Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 6.742 | ||
| EPS (TTM) ($) | -0.43 | ||
| Beta | 0.62 | ||
| Volatility % | 45.22 | ||
| 14-Day RSI | 31.68 | ||
| 14-Day ATR ($) | 0.077458 | ||
| 20-Day SMA ($) | 3.434555 | ||
| 12-1 Month Momentum % | 46.25 | ||
| 52-Week Range ($) | 2.2389 - 4.675 | ||
| Shares Outstanding (Mil) | 189.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Arbutus Biopharma Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Arbutus Biopharma Corp Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Arbutus Biopharma Corp Frequently Asked Questions
What is Arbutus Biopharma Corp(LTS:0SGC)'s stock price today?
The current price of LTS:0SGC is $3.18. The 52 week high of LTS:0SGC is $4.68 and 52 week low is $2.24.
When is next earnings date of Arbutus Biopharma Corp(LTS:0SGC)?
The next earnings date of Arbutus Biopharma Corp(LTS:0SGC) is 2025-02-28 Est..
Does Arbutus Biopharma Corp(LTS:0SGC) pay dividends? If so, how much?
Arbutus Biopharma Corp(LTS:0SGC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers